Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™, is pleased to share this update on the meaningful advancements the company has made across our core initiatives. Our team remains focused on advancing Precision Radionuclide Therapy™ (PRnT), our proprietary yttrium-90-based injectable hydrogel technology, to deliver accessible treatments for cancerous tumors in both humans (RadioGel®) and animals (IsoPet®).